Liminatus Pharma (NASDAQ:LIMN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Liminatus Pharma (NASDAQ:LIMN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Liminatus Pharma (NASDAQ:LIMN) was downgraded by analysts at
Wall Street
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation [Yahoo! Finance]
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation